Floatz logo

Pyrotinib

Liver Diseases

Sun Yat-sen UniversitySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Liver Diseases cohort.

Asset / SponsorPhaseRating
Pioglitazone
Yonsei University
Phase 4BBB
Empagliflozin
Military University Hospital, Prague
Phase 4BB
Hep-V Vax
University of Oxford
Phase 4BB
NEPENTHE
Anhui Provincial Hospital
Phase 4BB
Shen Pu Yang Gan Wan
Taipei Medical University WanFang Hospital
Phase 4BB

View all 39 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →